HbO2 Therapeutics Revenue and Competitors

Hemoglobin Oxygen Therapeutics LLC (HbO2 Therapeutics) is a leading developer and manufacturer of oxygen carrying solutions, a class of drug products that when administered intravenously can increase the amount of oxygen transported throughout the body. We have developed two products. Hemopure® [hemoglobin glutamer – 250 (bovine)], for use in humans, and Oxyglobin® [hemoglobin glutamer – 200 (bovine)]) for veterinary use. Oxyglobin is the only oxygen carrying solution approved by the FDA and the European Medicines Agency (EMA) to treat all cause canine anemia. Hemopure is approved in South Africa to treat adult surgical patients who are anemic, and in the Russian Federation for acute anemia, irrespective of etiology. In the US Hemopure is only available under investigational status through the FDA expanded access program to qualifying patients with severe, life threatening anemia for whom blood transfusion is not an option, and who have exhausted all other treatment options. Blood transfusion may not be an option due to religious beliefs, or because no compatible blood is available for a patient needing transfusion.